Glenmark Therapeutics Inc., a US-based company, has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC), a product that is comparable to the active ingredient in MiraLAX Powder for Solution, 17 grams from Bayer HealthCare LLC. According to Nielsen data, the MiraLAX product achieved annual sales of approximately $555.7 million in the latest 52-week period ending February 22, 2025.

The new product marks Glenmark’s entry into the market, which is expected to cater to the growing demand for a new supplier in this category. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed excitement about the launch, stating that it reflects the company’s commitment to meeting market needs and providing high-quality over-the-counter solutions for its customers.

The launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful is expected to give Glenmark a foothold in the market, which has been dominated by MiraLAX. The company’s entry into this category is a significant development, and it will be interesting to see how the market responds to this new competitor. With its commitment to providing high-quality products, Glenmark is likely to make a positive impact in the market. As the company continues to expand its portfolio, it will be worth monitoring to see how it fares in the competitive OTC market.

Mahavir International’s “Project Vatsalya – Pregnancy to Infancy” has been recognized for its outstanding efforts in eradicating malnutrition among women and children. The initiative received the prestigious Glenmark Nutrition Award 2025, which comes with a grant of Rs 2 lakh to support the expansion of the project. The award was established by the Glenmark Foundation and IDBRO to recognize organizations working towards eliminating malnutrition among pregnant and lactating women and children. Out of 403 nominations from across the country, Mahavir International’s Project Vatsalya was judged to be the best in the voluntary open category.

Dr. Veera Rashmi Saraswat, International Director of Women & Child Welfare – Vatsalya, presented the project to the grand jury in Mumbai, highlighting its efforts to combat malnutrition. The initiative is part of the National Nutrition Mission (Poshan Abhiyaan) and has been working tirelessly to address the issue of malnutrition among women and children. The award is a testament to the project’s dedication and commitment to improving the lives of these vulnerable groups.

The grant of Rs 2 lakh will enable Mahavir International to further extend the reach and impact of Project Vatsalya, making it a significant step towards a malnutrition-free society. The recognition is a proud moment for the organization, and Dr. Saraswat emphasized that the team will continue to work towards addressing this critical issue, which affects not only individual health but also the overall development of the country. With this award, Mahavir International’s Project Vatsalya has set a shining example for organizations working towards a similar cause, and its success will undoubtedly inspire others to follow in its footsteps.

Glenmark Pharmaceuticals has issued another recall, this time for approximately 1.5 million bottles of its generic attention deficit hyperactivity disorder (ADHD) medication, Strides Proudly Managed By Strides. The recall is due to potential irregularities in the labeling and packaging of the product.

According to the announcement, the affected products are Strides Fizzy Tab and Strides Fizzy Tabs, which are both used to treat ADHD. The recalled products were manufactured by Glenmark and are packaged in bottles containing 30, 60, or 100 tablets.

The recall affects products with expiration dates ranging from August 2022 to December 2024. The affected products were distributed nationwide in the United States to retail pharmacies and wholesalers.

Glenmark has issued a voluntary recall of the products, citing “labeling compliance issues” and “packaging irregularities.” The company is advising patients, pharmacists, and healthcare providers to stop using the affected products and return them to the original place of purchase for a replacement or refund.

This is not the first time Glenmark has issued a recall. In recent months, the company has faced numerous recalls due to similar labeling and packaging issues. In August, the company recalled dozens of generic medications, including blood pressure and antidepressant medications, due to packaging errors.

The FDA has not issued a formal recall, but it has launched an investigation into the matter. The agency is working closely with Glenmark to ensure that any affected products are removed from the market and patients are protected.

The recall highlights the importance of proper labeling and packaging in the pharmaceutical industry. It also underscores the need for companies like Glenmark to prioritize quality control measures to ensure that products meet regulatory standards. Patients who have been affected by the recall are advised to consult with their healthcare provider for alternative treatment options.

Glenmark Pharmaceuticals, a Mumbai-based company, has announced the launch of its generic version of Epinephrine injection multiple-dose vial in the US market. This product is eligible for 180 days of competitive generic therapy (CGT) exclusivity. The injection is used to treat severe allergic reactions, including anaphylaxis, and to increase mean arterial blood pressure in adult patients with septic shock. The product is bioequivalent and therapeutically equivalent to the reference-listed drug from BPI Labs, LLC.

According to Glenmark’s President and Business Head, Marc Kikuchi, the launch of this injection grows the company’s portfolio of products within the institutional channel and reinforces its commitment to providing quality and affordable alternatives for patients. The company’s product, Glenmark’s Epinephrine injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial, is priced competitively, with the Epinephrine injection 10 mg/10 mL (1 mg/mL) market achieving annual sales of approximately $42.7 million, according to IQVIA sales data for the 12-month period ending December 2024.

The company’s new product is expected to benefit patients by providing a more affordable and accessible alternative to the branded product. The 180-day exclusivity period ensures that Glenmark’s product will not face competition from other generic versions of the medication for at least six months, which will give it a competitive edge in the market. Overall, the launch of Glenmark’s Epinephrine injection is a significant milestone for the company, demonstrating its ability to bring affordable and effective treatments to patients in the US market.

Glenmark’s Telma brand, containing Telmisartan, has been a leading name in the treatment of hypertension, heart failure, and prevention of heart attack and stroke for two decades. The brand’s strength can be attributed to its strong brand identity, which has helped Glenmark successfully launch multiple line extensions and brands with enhanced formulations. According to a report by Pharmarack, flagship brands like Telma have seen strong growth with a CAGR of over 10% in the last five years, with some doubling their sales.

A 2015 study by Harvard Business Publishing Education revealed that Telma was introduced by Glenmark in 2003, when Ramipril was the leading molecule for treating hypertension. Glenmark’s successful build-up of Telma to a Rs 1000 crore brand is believed to be a result of a well-executed plan, as reported in the Harvard Business Review in 2015.

The key factors that contributed to Telma’s success include Glenmark’s focus on a niche market, long-term vision, patient strategy, effective R&D and product development, strong distribution market, and low-key marketing. Additionally, the company’s data-driven approach and strategic partnerships also played a crucial role. With 16 brands under its umbrella, Telma Mother brand has a combined turnover of Rs 1036 crore. As a testament to its success, Telma remains the strongest brand under Glenmark’s umbrella, making it a household name in the Indian pharmaceutical industry.